thalidomide has been researched along with Corneal Diseases in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Corneal Diseases: Diseases of the cornea.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turnbull, AMJ | 1 |
| Karmiris, E | 1 |
| Anderson, DF | 1 |
| Shuttleworth, GN | 1 |
| Cook, SD | 1 |
| Ropner, JE | 1 |
| Srinivasan, S | 1 |
| Perez-Gomez, I | 1 |
| O'Donnell, C | 1 |
| Batterbury, M | 1 |
3 other studies available for thalidomide and Corneal Diseases
| Article | Year |
|---|---|
Active IgGκ Multiple Myeloma Presenting With Crystalline Keratopathy.
Topics: Aged; Antineoplastic Agents; Bortezomib; Corneal Diseases; Dexamethasone; Drug Therapy, Combination; | 2018 |
Vanishing corneal epithelial crystals following thalidomide induced resolution of myeloma related paraproteinaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Corneal Diseases; Cyclophosphamide; Doxo | 2002 |
Corneal endothelial abnormalities associated with thalidomide toxicity.
Topics: Abnormalities, Drug-Induced; Adult; Corneal Diseases; Ectromelia; Endothelium, Corneal; Humans; Male | 2005 |